Infectious adverse events associated with novel Bruton tyrosine kinase (BTK) inhibitors in adults with chronic lymphocytic leukaemia: A meta-analysis of randomized controlled trials
- Journal
- British journal of haematology (Q1)
- Published
- 17 July 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Jędrzej Jerzy Janc, Tomasz Wróbel, Natalia Feliniak, Elżbieta Kalicińska
- PMID
- 42464867
- DOI
- 10.1111/bjh.70701
Why clinicians should know about it
- Picked for Hematology (top studies of the week, 19 July 2026): Meta-analysis of BTK inhibitors in CLL infections
- Picked for Infectious Diseases (top studies of the week, 19 July 2026).
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.